The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy. Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose.
González-Martín, A. et al.
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann.
Oncol. 34 , 833–848 (2023).
Pujade-Lauraine, E. et al.
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J.
Clin. Oncol.
32 , 1302–1308 (2014). Moore, K.
N. et al.
Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N.
Engl. J.
Med. 389 , 2162–2174 (2023).
Colombo, N. et al.
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet 407 , 1525–1537 (2026).
Lorusso, D. et al.
Nature Reviews Clinical Oncology published a clinical update in Oncology on 17 Jun 2026.
The item focuses on New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer.
Review the original article for the full source wording and details.